The Pryor-Cohen letter

The Pryor-Cohen letter

The lawmakers appended four questions arising from prior contacts with the company, which Berlex said it intends to answer this week. The questions are not included here because the context is not clear. However, they relate to the amount of drug covered by the price, Berlex's net revenue and profit per patient, the role of pharmacists and the prospects for deferred billing.

Dear Dr. Engel,

Congratulations on the approval of Betaseron. We are confident that this new, breakthrough therapy will be very helpful to many individuals who have multiple sclerosis (MS). We appreciate the fact that representatives of your company have been keeping our offices informed on a regular basis of the status of the approval, manufacturing, and pricing of the product.

We have received a letter of August 5th from your representatives which provides the latest details concerning the price and method for distribution